Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026-Acquisition

Biocon Limited's Board approved multiple items including audited FY2026 financial results and a final dividend of Rs. 0.50 per share (10%). The key announcement is the acquisition of the remaining ~2% stake in Biocon Biologics Limited (BBL), its material subsidiary, through a share swap. Biocon will issue up to 87,92,317 equity shares at Rs. 376.16 per share, aggregating Rs. 330.73 Crores, to BBL shareholders. Additionally, OCDs held by Goldman Sachs (1,125) and CCDs held by Edelweiss (1,06,86,044) will convert into BBL equity shares. Post-completion, Biocon's stake in BBL will reach ~99.99% on fully diluted basis, simplifying the corporate structure into a unified global biopharmaceutical leader. The board also appointed S R Batliboi & Associates LLP as new statutory auditors and added 5 new independent directors including industry veterans with pharma expertise.